Industry

Regenerative Medicine Global Market Report 2022-2031: Rising Demand for Organ Transplantations, Growth in Healthcare Expenditure, & Technological Advancements to Drive Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Regenerative Medicine Global Market Opportunities And Strategies To 2031” report has been added to ResearchAndMarkets.com’s offering. This report describes and explains the global regenerative medicine market and covers 2016 to 2021, termed the historic period, and 2021 to 2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report … [Read more…]

Global Patient Monitoring Devices Market Intelligence Report to 2027 – Featuring 100 Plus, Abbott Laboratories, Dexcom and Hill-Rom Holdings Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Patient Monitoring Devices Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Patient Monitoring Devices Market is projected to reach USD 84.10 billion by 2027 from USD 40.08 billion in 2021, at a CAGR 13.14% during the forecast period. Market Statistics: The report provides market … [Read more…]

Global Synthetic Biology, Logic Gated Therapies, Rapid Molecular Diagnostics & Peptide Synthesis Platforms Report 2022 – Featuring Arsenalbio, Beam Therapeutics, Circuit Bio and Genes2Me Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in Synthetic Biology, Logic Gated Therapies, Rapid Molecular Diagnostics and Peptide Synthesis Platforms” report has been added to ResearchAndMarkets.com’s offering. This report focuses on synthetic biology innovations around low cost gene synthesis and deployment of gene circuits for drug discovery and in therapies. Cell and gene therapies using logic gated circuits, … [Read more…]

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at the European Respiratory Society International Congress in Barcelona, Spain If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosing interstitial lung disease, addressing a high unmet need Findings … [Read more…]

Worldwide Over-The-Counter Veterinary Drugs Industry to 2032 – Look at Unique and Salient Factors That May Make a Huge Impact on Development – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Over-The-Counter (OTC) Veterinary Drugs Market Outlook to 2032” report has been added to ResearchAndMarkets.com’s offering. This report on the Over-The-Counter (OTC) veterinary drugs market offers a global industry analysis for 2017-2021 and an opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics. On conducting … [Read more…]

Epredia Expands Anatomical Pathology Business in Europe with Acquisition of Microm Microtech France and Laurypath

PORTSMOUTH, N.H.–(BUSINESS WIRE)–Epredia, a global leader in precision cancer diagnostics, today announced that its parent company PHC Holdings Corporation [TSE 6523] has acquired anatomical pathology suppliers Microm Microtech France (MMFrance) and Laurypath in a strategic expansion of Epredia’s presence in Europe. MMFrance and Laurypath, both founded in 1987 in Lyon, France, manufacture and supply anatomical … [Read more…]

Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022

BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer (NSCLC). The poster will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2022 that will … [Read more…]

IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer

Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy alone WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The … [Read more…]

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

Long-term data continue to reinforce benefits of Opdivo (nivolumab)-based combinations Response outcomes data continue to build upon the clinical evidence of Opdualag (nivolumab and relatlimab-rmbw) in advanced melanoma Exploratory analyses in non-small cell lung cancer and urothelial carcinoma support the potential benefit of immunotherapy in earlier stages of cancer PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #ESMO—Bristol Myers Squibb … [Read more…]

Biosimilars Global Market Opportunities and Strategies Report 2022: Long-term Forecast to 2026 & 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biosimilars Global Market Opportunities And Strategies To 2031” report has been added to ResearchAndMarkets.com’s offering. The global biosimilars market reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The market is expected to grow from $11,418.9 million in 2021 to … [Read more…]